Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Solaredge Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Solaredge Technologies Inc trades at $54.99 (market cap $3.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.9× Solaredge Technologies Inc's market cap, and Solaredge Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SEDG | |
|---|---|---|
Market Cap | $39.89B | $3.36B |
Sector | Health | Technology |
52-Week High | $491.22 | $78.51 |
52-Week Low | $278.09 | $24.42 |
Enterprise Value | $38.15B | $3.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SolarEdge Technologies (SEDG) trades at $55.18, up 0.77% on the day, with a neutral technical signal and mixed analyst sentiment. The company shows improving operational cash flow ($104M in 2025) but continues to report significant losses (-$405M net income). Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, while solar sector momentum from AI data center demand provides tailwinds.
The stock faces fundamental challenges with negative margins and high debt, though cash flow stabilization and sector growth offer potential upside. Key risks include persistent profitability issues and policy uncertainty, while analyst consensus remains cautious with a $34.99 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
